Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05302921 · ClinicalTrials.gov registry record · Phase 2
Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors
A Phase 2 study, sponsored by Children's National Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT05302921 is a Phase 2 study that has completed, run by Children's National Research Institute. The registered enrollment target is 5 participants.
The verdict
NCT05302921, a Phase 2 study, has completed, sponsored by Children's National Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
The is a phase II, single arm, open-label, multi-site trial studying the combination of cryoablation therapy and dual checkpoint inhibition with nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4) given at the recommended phase 2 dose (RP2D) in pediatric and young adult patients with relapsed or refractory solid tumors.
Interventions
- DRUG Nivolumab
- DRUG Ipilimumab
- PROCEDURE Cryoablation Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2022-02-18 |
| Est. Completion | 2024-03-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05302921
The ClinicalTrials.gov registry entry for NCT05302921 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's National Research Institute, which has 92 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Nivolumab is the first listed.
NCT05302921 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05302921 about?
NCT05302921 is a clinical study titled "Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors". The is a phase II, single arm, open-label, multi-site trial studying the combination of cryoablation therapy and dual checkpoint inhibition with nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4) given at the recommended phase 2 dose (RP2D) in pediatric and young adult patients with relapsed or refr...
What is the current status of trial NCT05302921?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2022-02-18. Estimated completion is 2024-03-12.
What interventions are being tested in trial NCT05302921?
The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (DRUG), Cryoablation Therapy (PROCEDURE).
Who is sponsoring clinical trial NCT05302921?
This trial is sponsored by Children's National Research Institute, which has 92 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.